

Table 1: Patient characteristics at baseline*

Characteristic	Budesonide N=311	Nedocromil N=312	Placebo N=418
Age - yr	9.0±2.1	8.8±2.1	9.0±2.2
Race or ethnic group - no. [%]			
Non-Hispanic white	201 [64.6]	218 [69.9]	292 [69.9]
Non-Hispanic black	44 [14.1]	38 [12.2]	56 [13.4]
Hispanic	32 [10.3]	29 [9.3]	37 [8.9]
Other	44 [10.9]	27 [8.7]	33 [7.9]
Gender - %			
Female	41.8	34.0	44.0
Male	58.2	66.0	56.0
Age at onset of asthma - yr	3.1±2.3	3.1±2.4	3.0±2.6
Time since diagnosis of asthma - yr	5.2	5.0	4.9
Treatments in 6 mo before enrollment - %			
Cromolyn or nedocromil	42.8	47.4	38.3
Inhaled corticosteroid	40.5	36.5	35.9
Oral corticosteroid	34.4	30.1	38.8
Severity of asthma - %			
Moderate	53.4	51.6	51.7
Mild	46.6	48.4	48.3
Daily diary card			
Episode free days - no./mo	9.7±7.8	9.9±8.1	9.6±7.6
Albuterol for symptoms - puffs/wk	10.4±9.8	10.5±9.8	10.2±9.6
Night awakenings - no./mo	0.9±1.7	1.0±1.7	0.8±1.5
FEV₁ before bronchodilator use - % of predicted	93.6±14.4	93.4±14.5	94.2±14.0
FEV₁ after bronchodilator use - % of predicted	103.2±13.2	102.3±12.7	103.3±12.2
Airway responsiveness to methacholine [FEV₁ PC₂₀] - mg/mL**	1.1±3.3	1.2±3.3	1.1±3.3
Height - percentile	56.8±28.0	56.0±28.7	55.3±28.8
Follow-up - yr	4.3±0.8	4.3±0.7	4.3±0.7

* All values are means; plus-minus values are means ± SD except as noted otherwise

** Values are geometric means ± SD

Table adapted from data published in New Engl J Med 2000; 343:1056